137 related articles for article (PubMed ID: 37093266)
41. Pharmacokinetics and safety of IBI301 versus rituximab in patients with CD20
Jiang B; Ke X; Zhang Q; Xu W; Su H; Huang J; Zhang M; Wang H; Jin C; Zhu J; Liu L; Cai Z; Zhao X; Zhou J; Zhang X; Liu J; Zhou H; Yu J; Sun X; Qi J; Qiu L
Sci Rep; 2020 Jul; 10(1):11676. PubMed ID: 32669656
[TBL] [Abstract][Full Text] [Related]
42. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles.
Cunningham D; Hawkes EA; Jack A; Qian W; Smith P; Mouncey P; Pocock C; Ardeshna KM; Radford JA; McMillan A; Davies J; Turner D; Kruger A; Johnson P; Gambell J; Linch D
Lancet; 2013 May; 381(9880):1817-26. PubMed ID: 23615461
[TBL] [Abstract][Full Text] [Related]
43. Preference for subcutaneous or intravenous administration of rituximab among patients with untreated CD20+ diffuse large B-cell lymphoma or follicular lymphoma: results from a prospective, randomized, open-label, crossover study (PrefMab).
Rummel M; Kim TM; Aversa F; Brugger W; Capochiani E; Plenteda C; Re F; Trask P; Osborne S; Smith R; Grigg A
Ann Oncol; 2017 Apr; 28(4):836-842. PubMed ID: 28031173
[TBL] [Abstract][Full Text] [Related]
44. Efficacy, Safety and Immunogenicity of MB02 (Bevacizumab Biosimilar) versus Reference Bevacizumab in Advanced Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Phase III Study (STELLA).
Trukhin D; Poddubskaya E; Andric Z; Makharadze T; Bellala RS; Charoentum C; Yañez Ruiz EP; Fulop A; Hyder Ali IA; Syrigos K; Katgi N; Lopez Chuken YA; Rumyana I; Reyes-Igama J; Costamilan RC; Del Campo García A; Florez A; Paravisini A; Millan S;
BioDrugs; 2021 Jul; 35(4):429-444. PubMed ID: 33914256
[TBL] [Abstract][Full Text] [Related]
45. Comparison of biosimilar CT-P10 and innovator rituximab in patients with rheumatoid arthritis: a randomized controlled Phase 3 trial.
Park W; Božić-Majstorović L; Milakovic D; Berrocal Kasay A; El-Khouri EC; Irazoque-Palazuelos F; Molina FFC; Shesternya P; Miranda P; Medina-Rodriguez FG; Wiland P; Jeka S; Chavez-Corrales J; Garmish O; Linde T; Rekalov D; Hrycaj P; Krause A; Fomina N; Piura O; Abello-Banfi M; Suh CH; Shim SC; Lee SJ; Lee SY; Kim SH; Yoo DH
MAbs; 2018; 10(6):934-943. PubMed ID: 30010481
[TBL] [Abstract][Full Text] [Related]
46. Scientific rationale underpinning the development of biosimilar rituximab in hematological cancers and inflammatory diseases.
Jurczak W; Cohen S; Illidge TM; Silva AD; Amersdorffer J
Future Oncol; 2019 Dec; 15(36):4223-4234. PubMed ID: 31718287
[TBL] [Abstract][Full Text] [Related]
47. Cardiotoxicity with rituximab, cyclophosphamide, non-pegylated liposomal doxorubicin, vincristine and prednisolone compared to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone in frontline treatment of patients with diffuse large B-cell lymphoma: A randomised phase-III study from the Austrian Cancer Drug Therapy Working Group [Arbeitsgemeinschaft Medikamentöse Tumortherapie AGMT](NHL-14).
Fridrik MA; Jaeger U; Petzer A; Willenbacher W; Keil F; Lang A; Andel J; Burgstaller S; Krieger O; Oberaigner W; Sihorsch K; Greil R
Eur J Cancer; 2016 May; 58():112-21. PubMed ID: 26990931
[TBL] [Abstract][Full Text] [Related]
48. Efficacy and Safety of Bevacizumab Biosimilar FKB238 Versus Originator Bevacizumab: Results from AVANA, a Phase III Trial in Patients with Non-Squamous Non-Small-Cell Lung Cancer (non-sq-NSCLC).
Syrigos K; Abert I; Andric Z; Bondarenko IN; Dvorkin M; Galic K; Galiulin R; Kuchava V; Sriuranpong V; Trukhin D; Zhavrid E; Fu D; Kassalow LM; Jones S; Bashir Z;
BioDrugs; 2021 Jul; 35(4):417-428. PubMed ID: 34264503
[TBL] [Abstract][Full Text] [Related]
49. Role of Rituximab and Rituximab Biosimilars in Diffuse Large B-Cell Lymphoma.
Coleman M; Lammers PE; Ciceri F; Jacobs IA
Clin Lymphoma Myeloma Leuk; 2016 Apr; 16(4):175-81. PubMed ID: 26906106
[TBL] [Abstract][Full Text] [Related]
50. Efficacy and safety of switching from rituximab to biosimilar CT-P10 in rheumatoid arthritis: 72-week data from a randomized Phase 3 trial.
Shim SC; Božić-Majstorović L; Berrocal Kasay A; El-Khouri EC; Irazoque-Palazuelos F; Cons Molina FF; Medina-Rodriguez FG; Miranda P; Shesternya P; Chavez-Corrales J; Wiland P; Jeka S; Garmish O; Hrycaj P; Fomina N; Park W; Suh CH; Lee SJ; Lee SY; Bae YJ; Yoo DH
Rheumatology (Oxford); 2019 Dec; 58(12):2193-2202. PubMed ID: 31184752
[TBL] [Abstract][Full Text] [Related]
51. Efficacy and Safety of Proposed Bevacizumab Biosimilar BE1040V in Patients With Metastatic Colorectal Cancer: A Phase III, Randomized, Double-blind, Noninferiority Clinical Trial.
Rezvani H; Mortazavizadeh SM; Allahyari A; Nekuee A; Najafi SN; Vahidfar M; Ghadyani M; Khosravi A; Qarib S; Sadeghi A; Esfandbod M; Rajaeinejad M; Rezvani A; Hajiqolami A; Payandeh M; Shazad B; Anjidani N; Meskinimood S; Alikhasi A; Karbalaeian M; Salari S
Clin Ther; 2020 May; 42(5):848-859. PubMed ID: 32334845
[TBL] [Abstract][Full Text] [Related]
52. Assessing the Interchangeability of AVT02 and Humira
Feldman SR; Kay R; Reznichenko N; Sobierska J; Dias R; Otto H; Haliduola HN; Sattar A; Ruffieux R; Stroissnig H; Berti F
BioDrugs; 2023 Jul; 37(4):551-567. PubMed ID: 37204631
[TBL] [Abstract][Full Text] [Related]
53. [Clinical features and outcomes of newly diagnosed follicular lymphoma concurrent with diffuse large B-cell lymphoma component].
Lin ZJ; Zha J; Yi SH; Li ZF; Ping LY; He XH; Yu HF; Zheng Z; Xu W; Chen FL; Xie Y; Chen BY; Zhang HL; Wang L; Ding KY; Li WY; Yang HY; Zhao WL; Qiu LG; Li ZM; Song YQ; Xu B
Zhonghua Xue Ye Xue Za Zhi; 2022 Jun; 43(6):456-462. PubMed ID: 35968587
[No Abstract] [Full Text] [Related]
54. Efficacy and Safety of ABP 798: Results from the JASMINE Trial in Patients with Follicular Lymphoma in Comparison with Rituximab Reference Product.
Niederwieser D; Hamm C; Cobb P; Mo M; Forsyth C; Tucci A; Hanes V; Delwail V; Hajek R; Chien D
Target Oncol; 2020 Oct; 15(5):599-611. PubMed ID: 33044684
[TBL] [Abstract][Full Text] [Related]
55. AURIEL-PsO: a randomized, double-blind phase III equivalence trial to demonstrate the clinical similarity of the proposed biosimilar MSB11022 to reference adalimumab in patients with moderate-to-severe chronic plaque-type psoriasis.
Hercogová J; Papp KA; Chyrok V; Ullmann M; Vlachos P; Edwards CJ
Br J Dermatol; 2020 Feb; 182(2):316-326. PubMed ID: 31206593
[TBL] [Abstract][Full Text] [Related]
56. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study.
Chiappella A; Martelli M; Angelucci E; Brusamolino E; Evangelista A; Carella AM; Stelitano C; Rossi G; Balzarotti M; Merli F; Gaidano G; Pavone V; Rigacci L; Zaja F; D'Arco A; Cascavilla N; Russo E; Castellino A; Gotti M; Congiu AG; Cabras MG; Tucci A; Agostinelli C; Ciccone G; Pileri SA; Vitolo U
Lancet Oncol; 2017 Aug; 18(8):1076-1088. PubMed ID: 28668386
[TBL] [Abstract][Full Text] [Related]
57. Rituximab-CHOP With Early Rituximab Intensification for Diffuse Large B-Cell Lymphoma: A Randomized Phase III Trial of the HOVON and the Nordic Lymphoma Group (HOVON-84).
Lugtenburg PJ; de Nully Brown P; van der Holt B; D'Amore FA; Koene HR; de Jongh E; Fijnheer R; van Esser JW; Böhmer LH; Pruijt JF; Verhoef GE; Hoogendoorn M; Bilgin MY; Nijland M; van der Burg-de Graauw NC; Oosterveld M; Jie KG; Larsen TS; van der Poel MW; Leijs MB; Silbermann MH; van Marwijk Kooy M; Beeker A; Kersten MJ; Doorduijn JK; Tick LW; Brouwer RE; Lam KH; Burggraaff CN; de Keizer B; Arens AI; de Jong D; Hoekstra OS; Zijlstra-Baalbergen JM
J Clin Oncol; 2020 Oct; 38(29):3377-3387. PubMed ID: 32730183
[TBL] [Abstract][Full Text] [Related]
58. Extension Study of PF-05280586, a Potential Rituximab Biosimilar, Versus Rituximab in Subjects With Active Rheumatoid Arthritis.
Cohen SB; Burgos-Vargas R; Emery P; Jin B; Cronenberger C; Vázquez-Abad MD
Arthritis Care Res (Hoboken); 2018 Nov; 70(11):1598-1606. PubMed ID: 29692005
[TBL] [Abstract][Full Text] [Related]
59. Efficacy and safety of two pegfilgrastim biosimilars: Tripegfilgrastim and pegteograstim.
Kang KW; Lee BH; Jeon MJ; Yu ES; Kim DS; Lee SR; Sung HJ; Choi CW; Park Y; Kim BS
Cancer Med; 2020 Sep; 9(17):6102-6110. PubMed ID: 32633471
[TBL] [Abstract][Full Text] [Related]
60. Comparison of pharmacokinetics, pharmacodynamics, safety, and immunogenicity of teriparatide biosimilar with EU- and US-approved teriparatide reference products in healthy men and postmenopausal women.
Fenwick S; Vekariya V; Patel R; Hajela P; Modi K; Kale P; Nath A
Osteoporos Int; 2023 Jan; 34(1):179-188. PubMed ID: 36287230
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]